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Abstract
Background: The anxiety-reducing effect of long-term administration of serotonin reuptake inhibitors is usually seen only 
in subjects with anxiety disorders, and such patients are also abnormally inclined to experience a paradoxical anxiety-
enhancing effect of acute serotonin reuptake inhibition. These unique responses to serotonin reuptake inhibitors in anxiety-
prone subjects suggest, as do genetic association studies, that inter-individual differences in anxiety may be associated with 
differences in serotonergic transmission.
Methods: The one-third of the animals within a batch of Wistar rats most inclined to spend time on open arms in the elevated 
plus maze were compared with the one-third most inclined to avoid them with respect to indices of brain serotonergic 
transmission and how their behavior was influenced by serotonin-modulating drugs.
Results: “Anxious” rats displayed higher expression of the tryptophan hydroxylase-2 gene and higher levels of the tryptophan 
hydroxylase-2 protein in raphe and also higher levels of serotonin in amygdala. Supporting these differences to be important 
for the behavioral differences, serotonin depletion obtained by the tryptophan hydroxylase-2 inhibitor p-chlorophenylalanine 
eliminated them by reducing anxiety in “anxious” but not “non-anxious” rats. Acute administration of a serotonin reuptake 
inhibitor, paroxetine, exerted an anxiety-enhancing effect in “anxious” but not “non-anxious” rats, which was eliminated by 
long-term pretreatment with another serotonin reuptake inhibitor, escitalopram.
Conclusions: Differences in an anxiogenic impact of serotonin, which is enhanced by acute serotonin reuptake inhibitor 
administration, may contribute to differences in anxiety-like behavior amongst Wistar rats.
Keywords: Serotonin, anxiety, serotonin reuptake inhibitors, tryptophan hydroxylase 2, elevated plus maze
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Introduction
Many authors have suggested inter-individual differences in 
serotonergic transmission to be the cause of inter-individual dif-
ferences in proneness for anxiety (Lesch et al., 1996; Maron et al., 
2012; Mosienko et al., 2012; Araragi and Lesch, 2013). The spe-
cific response to serotonin reuptake inhibitors (SRIs) displayed 
by subjects with anxiety disorders may be regarded as indirect 
support for this assumption. Thus, while traditional anxiolytic 
drugs acting by modulation of the GABA A  receptor complex, 
such as barbiturates and benzodiazapines, exert nonspecific 
sedation also in nonanxious subjects and also dampen rational 
fear, long-term administration of SRIs results in an impressive 
symptom reduction in patients with anxiety disorders (Den 
Boer and Westenberg, 1988; Modigh et al., 1992; Nutt et al., 1999; 
Zohar and Westenberg, 2000) while exerting no (Furlan et  al., 
2004) or merely subtle fear- and anxiety-reducing effects in 
healthy controls (Simmons and Allen, 2011). Reciprocally, while 
acute administration of SRIs (Ramos et  al., 1993; Nutt et  al., 
1999; Sinclair et al., 2009) or the serotonin releasing agent fen-
fluramine (Targum and Marshall, 1989) often increases anxiety 
in patients with anxiety disorders, such as panic disorder, and 
in subjects with anxiety-related personality traits (Rammsayer 
and Netter, 1990), this response is generally absent or mild in 
nonanxious subjects exposed to these drugs.
In the same vein, genetic studies have revealed serotonin-
related genes to be associated with anxiety-related personal-
ity traits (Lesch et al., 1996; Melke et al., 2003; Sen et al., 2004) 
and anxiety-related endophenotypes such as amygdalar reac-
tivity (Hariri et  al., 2002; Furmark et al., 2009). Methodological 
limitations, however, still hamper the possibility to measure the 
status of brain serotonergic neurotransmission in humans, and 
there is hence limited support for aberrations in serotonergic 
activity in anxiety-prone subjects and also no consensus regard-
ing if serotonin should be regarded mainly as anxiety enhancing 
(Eison, 1990; Graeff and Zangrossi, 2010; Andrade et al., 2013) or 
anxiety reducing (Nutt et al., 1999; Graeff and Zangrossi, 2010; 
Donner et al., 2012), or if it may even exert both effects (Graeff 
and Zangrossi, 2010). To what extent long-term administration 
of SRIs enhances (Nutt et  al., 1999; Bell et  al., 2002) or damp-
ens (Salchner and Singewald, 2006) a serotonergic influence on 
anxiety-regulating circuits, or may exert both effects (Graeff and 
Zangrossi, 2010), likewise remains a matter of controversy.
Numerous animal studies suggest that manipulation of 
brain serotonergic neurotransmission, obtained by drugs 
(Pinheiro et al., 2007) or genetic manipulation (Fernandez and 
Gaspar, 2012; Mosienko et  al., 2012; Araragi and Lesch, 2013), 
leads to changes in anxiety-related behavior as reflected, for 
example, by avoidance of open arms in the elevated plus maze 
(EPM). However, to what extent inter-individual differences with 
respect to EPM behavior within a batch of experimental rats is 
associated with inter-individual differences in brain serotoner-
gic transmission, and if eliminating the influence of serotonin 
may abolish such behavioural differences, is unknown.
Previous studies of EPM performance in outbred Wistar rats 
support the existence of relatively stable (test vs retest) inter-
individual variations that are sufficiently robust to justify the 
characterization of the rats as more or less “anxious” (Schneider 
et al., 2011). These differences are associated with other aspects 
of behavior (Ho et al., 2002; Borta et al., 2006) and brain neuro-
chemistry (Schwarting et al., 1998), and they have also provided 
the basis for the breeding of strains characterized by low or high 
anxiety-like behavior (Liebsch et al., 1998). The aim of the pre-
sent study was to utilize these inter-individual differences in 
Wistar rats with respect to EPM behavior to shed further light 
on 3 long-debated issues: 1) are inter-individual differences in 
anxiety to some extent caused by inter-individual differences 
in serotonergic transmission, 2)  is the possible contribution of 
serotonergic neurotransmission to inter-individual differences 
in anxiety best described as anxiety promoting or anxiety reduc-
ing, and 3) is the influence of SRIs, administered acutely or on a 
continuous basis, respectively, best described as a facilitation or 
a dampening of a serotonergic influence on anxiety-generating 
circuits.
Materials and Methods
Animals
Male Wistar rats (Taconic, Ejby, Denmark), aged 10 to 11 weeks 
at arrival, were housed with a 12-h-light/-dark cycle (lights on 
at 6 am) and with standard chow and water available ad libi-
tum. The animals were allowed 1 week of acclimatization after 
arrival before being subjected to any behavioral tests. In all 
experiments, animals were subdivided on the basis of how they 
performed in the EPM, the one-third most prone to spend time 
on the open arm constituting one group, presumably charac-
terized by low anxiety (high open arm, HO) and the one-third 
most prone to avoid it constituting the other, tentatively more 
anxious group (low open arm, LO). The middle group was thus 
excluded from all further analyses in order to avoid misclassifi-
cation of animals belonging to this group but being close to one 
of the extreme groups.
All procedures were carried out with approval of the local eth-
ics committee and in accordance with institutional guidelines.
Experimental Outline
Experiment I
Forty-eight animals were tested in the EPM for categorization 
into HO (one-third) and LO (one-third) rats 2 weeks before being 
subjected to a test of unconditioned noise burst-elicited startle 
(lasting for 15 minutes and comprising 30 bursts with 30-sec-
ond intervals at 95 dB and with 20 ms duration per burst; Med 
Associates, St. Albans, VT) followed 1 week later by a forced-
swim test (comprising two 10-minute sessions separated by 24 
hours). One week after the forced-swim test, the animals were 
killed and their brains extracted for assessment of gene expres-
sion using real-time PCR (TaqMan), tryptophan hydroxylase 2 
(TPH2) levels using Western blot, and serotonin and 5-hydrox-
yindoeacetic acid (5-HIAA) levels using high-pressure liquid 
chromatography (HPLC) (see supplementary Materials and 
Methods).
Experiment II
Sixty animals were pretested in the EPM for categorization into 
HO (one-third) and LO (one-third) rats. After 3 weeks, treatment 
with the tryptophan hydroxylase inhibitor para-chlorophenyla-
lanine (p-CPA) was initiated. Animals were again tested in the 
EPM 24 hours after the last injection. The following day, the ani-
mals were sacrificed; the brains from one-third of them were 
extracted for validation of serotonin depletion.
Experiment III
One hundred twenty animals were pretested in the EPM for cat-
egorization into HO (one-third) and LO (one-third), whereupon 
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one-half of the animals in each group received escitalopram p.o. 
in food pellets and the other one-half control pellets. After 5 weeks 
of treatment, the animals received one injection of paroxetine or 
vehicle 1 hour before a second EPM session was undertaken.
Drugs
p-CPA (Sigma-Aldrich, St Louis, MO) was dissolved in 0.9% saline 
and administered i.p. as one injection of 300 mg/kg per day for 
3 days with the last injection being given 24 hours before the 
EPM test. Escitalopram oxalate (Shodana Labs, Hyderabad, India) 
was admixed into food pellets (Lantmännen, Kimstad, Sweden) 
at a concentration (0.65 g/kg) aimed at providing a daily dose of 
25 to 30 mg/kg (El Khoury et al., 2006). Paroxetine hydrochloride 
(Jai Radhe Chemicals, Ahmedabad, India) was dissolved in 0.9% 
saline and administered s.c. at a dose of 10 mg/kg 1 hour before 
the EPM test.
EPM
A standard black acrylic plastic rat EPM (Med Associates) was 
placed in a quiet room with a light level in the center of the 
maze of 35 lx. All tests lasted for 5 minutes. In the experiments 
comprising 2 tests, the EPM apparatus was placed in a room new 
to the animals at session 2 in order to minimize habituation 
effects (Schneider et al., 2011).
Biochemical Analyses
See supplementary Materials and Methods.
Statistical Analyses
Student’s t test was used to compare groups with respect to bio-
chemical data. Due to non-normal distribution of the relevant 
behavioral parameters in drug-treated animals, EPM data were 
log-transformed according to the formula log10(x + 1), with x 
being the behavioral parameter in question, before being ana-
lyzed using ANOVA followed by LSD posthoc test. Interactions 
were tested using 2-way ANOVA when appropriate. Pearson cor-
relation was used to calculate correlations.
Results
Test-Retest Correlations
Justifying the categorization of rats into more or less anxious, we 
could, by examining the test-retest stability with respect to EPM 
performance in animals that had obtained no active pharmaco-
logical treatment between the tests, confirm the previous obser-
vation (Schneider et al., 2011) of relatively stable inter-individual 
differences within an outbred batch of Wistar rats (experiment 
II, n = 20, r = 0.63, P = .003; experiment III, n = 20, r = 0.68, P = .001). 
In line with this, 18 of 20 (experiment II) and 16 of 20 (experi-
ment III) animals in the nontreated groups were found to be in 
the same HO/LO group in the second EPM session as in the first.
Relationship to Other Behavioral Tests
Experiment I  revealed that EPM behavior (time spent on open 
arms) does not correlate with average startle amplitude (n = 48, 
r = 0.02, P = .9) or with immobility in the forced-swim test (n = 48, 
r = -0.08, P = .6); in the same vein, no differences between HO 
and LO animals with respect to startle response (average startle 
amplitude: HO 322.21 ± 58.27, LO 290.56 ± 43.8, P = .6, n = 16 per 
group, data given as means ± SEM) or FST performance (seconds 
of immobility: HO 80.25 ± 7.24, LO 98.0 ± 9.67, P= .15, n = 16 per 
group, data given as means ± SEM) were found.
Biochemical Analyses
A comparison of LO and HO animals revealed the LO rats to be 
characterized by significantly higher raphe expression of several 
genes expressed more or less exclusively by serotonergic neurons, 
including the TPH2 gene (Figure  1A), but showed no difference 
with respect to serotonin-related genes that are also expressed by 
other cells. TPH2 levels being elevated in the raphe region of LO 
animals was confirmed using Western blot (Figure 1B). Moreover, 
analysis of serotonin and the serotonin metabolite 5-HIAA using 
HPLC revealed higher serotonin levels in the amygdala of LO rats 
but no difference with respect to 5-HIAA levels and no differences 
in hippocampus and striatum (Figure 1C).
Behavioral and Biochemical Effects of p-CPA
Administration of the tryptophan hydroxylase inhibitor (p-CPA) 
led to an increase in time spent on open arms (Figure 2A) and 
entries onto open arms (Figure  2B) in LO rats but exerted no 
corresponding effect in the HO group, hence abolishing the 
behavioral difference between the 2 groups. HPLC analysis of ser-
otonin content in brain stem and amygdala confirmed a robust 
decrease of both serotonin (forebrain: -95.2 ± 0.7%; P ≤ .001; brain-
stem: -97.6 ± 0.4%; P ≤ .001) and 5-HIAA (forebrain: -97.8 ± 0.6%; 
brainstem: P ≤ .001; -93.0 ± 1.1%; P ≤ .001) levels (n = 9–10/group) in 
p-CPA–treated animals (n = 9–10/group) with no tendencies for 
any differences between LO and HO animals in this regard.
Behavioral Response to Acute SRI Administration
Acute administration of paroxetine exerted an anxiogenic effect, 
that is, decreased the time spent on, as well as entries onto, 
open arms in otherwise untreated LO animals. No such effect 
was seen in the corresponding HO group, albeit a trend towards 
decreased entries to open arms was observed (Figure  3A-B, 
upper graphs).
Behavioral Response to Subchronic SRI 
Administration
Pretreatment with escitalopram (p.o.) for 5 weeks caused a mod-
est and nonsignificant reduction in time spent on open arms 
in otherwise untreated LO rats but totally prevented the anxi-
ogenic-like effect of acute administration of another SRI, par-
oxetine, in these animals, the interaction between escitalopram 
and paroxetine being significant (P < .007, F = 8.281, df = 1). HO 
rats given subchronic escitalopram displayed reduced time on 
open arms; like otherwise untreated HO rats and escitalopram-
treated LO rats, they did not, however, display an anxiogenic-
like response to acute administration of paroxetine. Subchronic 
escitalopram administration hence eliminated all differences 
with respect to open arm duration and entries between LO and 
HO animals (Figures 3A-B, lower graphs).
Effects of Escitalopram and Paroxetine on Entries 
into Closed Arms
To evaluate if the effect of acute SRI administration on anxi-
ety as assessed using EPM could be secondary to an effect on 
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locomotion in general, we also measured entries into closed 
arms. This parameter was not different in untreated HO rats 
(3.9 ± 0.7) compared with untreated LO animals (4.0 ± 0.9; n.s.). 
Administration of paroxetine did not cause a significant reduc-
tion in the number of entries into closed arms in either HO 
(3.4 ± 0.4: n.s.) or LO rats (2.3 ± 0.6; n.s.); hence, there were no 
significant differences between any of the groups displayed 
in Figure  3A with respect to closed arms entries. Subchronic 
administration of escitalopram did not influence closed arm 
entries in HO rats (4.7 ± 0.6, n.s.) but exerted a modest reduction 
in LO rats (2.3 ± 0.5) that was nonsignificant when these animals 
were compared with controls not given escitalopram but of suf-
ficient magnitude to make this group differ significantly from 
the corresponding HO group (P < .01). Administration of parox-
etine to escitalopram-treated LO rats, however, counteracted 
this effect of escitalopram (4.1 ± 0.67); this group hence differed 
neither from HO rats given escitalopram plus NaCl nor from HO 
rats given escitalopram plus paroxetine, but did differ from LO 
rats given escitalopram plus NaCl (P < .05).
Discussion
This study suggests that inter-individual differences in anxiety 
in a batch of male Wistar rats may be partly explained by differ-
ences in an anxiogenic influence of serotonin. While animals 
prone to anxiety-related behavior (LO) hence displayed indices 
of enhanced serotonergic transmission, including enhanced 
TPH2 expression, arresting serotonergic transmission by 
inhibiting this enzyme reduced anxiety-like behavior selec-
tively in these rats, thereby making the differences in behavior 
Figure 2. Percentage of time spent on open arms (A) and number of entries made onto open arms (B) by animals receiving either saline or para-chlorophenylalanine 
(p-CPA). Values are given as means ± SEM. n = 10 in all groups. Significance symbols (*) associated with a specific bar represent level of significance for the difference 
between rats of the same group (high open arm [HO] and low open arm [LO], respectively) given saline or p-CPA, respectively: n.s. nonsignificant, **P < .01, ***P < .001.
Figure 1. Expression of serotonin-related genes in the raphe nuclei (A), levels of the tryptophan hydroxylase 2 (TPH2) protein in the raphe nuclei (B), and levels of 
serotonin (5-HT) and 5-hydroxyindoeacetic acid (5-HIAA) in amygdala, hippocampus, and striatum (C) (n = 10 in all groups in A and B, n = 6 in all groups in C). In A and 
B, values of low open arm (LO) rats are expressed as geometric means ± SEM relative to the high open arm (HO) group, the mean of which is set to 1. In C, values are 
given as means ± SEM. Significance symbols (*) associated with a specific bar represent levels of significance for the difference between HO and LO animals: n.s. non-
significant, *P < .05, **P < .01.
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between LO and HO animals disappear. Further, similar to the 
human situation and in line with the assumption that non-
anxious and anxious animals differ with respect to the mag-
nitude of an anxiogenic-like serotonergic influence, we found 
animals with high baseline anxiety-like behavior to display 
a greater anxiogenic-like response to acute administration 
of an indirect serotonin agonist, the SRI paroxetine. Finally, 
long-term administration of an SRI, which has previously 
been suggested to cause an adaptive downregulation of the 
anxiogenic influence of serotonin (Salchner and Singewald, 
2006; Graeff and Zangrossi, 2010), was found to blunt the anx-
iogenic-like effect of acute SRI administration in LO animals, 
hence making them similar to HO rats in this regard. The 
results support the view that inter-individual differences with 
respect to an anxiogenic influence of serotonin are important 
for inter-individual differences in anxiety-related behavior 
and that the anxiety-reducing effect of long-term SRI admin-
istration may be attributed to a downregulation of such an 
influence.
Our claim that LO animals are characterized by enhanced 
serotonergic activity is based mainly on the observation that 
they display enhanced expression of the gene encoding the 
rate-limiting enzyme for the synthesis of serotonin, TPH2, in 
the region where serotonergic cell bodies are situated, the raphe 
nuclei, and that this increase in TPH2 expression was confirmed 
by means of Western-blot assessment of the TPH2 protein. Our 
findings are in line with previous studies showing that raphe 
TPH2 expression is enhanced in rodents rendered anxious by 
genetic modulation of nonserotonergic genes (Jahanshahi et al., 
2011) or by subchronic infusion of a corticotropin-releasing 
agent into the basolateral amygdaloid complex (Donner et al., 
2012). Moreover, the importance of nongenetic factors in this 
context is illustrated by the observations that chronic restraint 
stress, maternal deprivation during early life combined with 
social defeat at adulthood, and neonatal administration of 
lipopolysaccharides are all interventions that produce both 
anxiety-like behavior in the EPM and elevated TPH2 expression 
in rodents (Chamas et al., 1999; Gardner et al., 2009; Sidor et al., 
2010). In contrast, reduced raphe TPH2 expression was reported 
in Wistar rats displaying a low degree of exploratory behavior; 
this study, however, did not employ the EPM paradigm but a test 
based on exploration of novel and familiar objects and assumed 
to reflect both motivation and anxiety (Alttoa et al., 2010).
The apparent enhancement of serotonergic transmission 
in animals displaying enhanced anxiety-like behavior could 
be regarded either as support for an anxiety-promoting role of 
serotonin or explained in terms of compensatory mechanisms 
aiming to dampen the influence of various anxiety-promoting 
circuits. In the present study, we show a TPH2 inhibitor, p-CPA, 
to reduce anxiety-like behavior in anxious LO rats but not in 
nonanxious HO animals, hence eliminating the behavioral dif-
ference between the 2 groups. While the anxiolytic-like effect 
of p-CPA in this paradigm, which supports an anxiogenic-like 
influence of this transmitter, is well known (Treit et  al., 1993; 
Näslund et al., 2013), this is, to our knowledge, the first study 
using p-CPA to address the possible causal relationship between 
baseline differences in serotonergic transmission and EPM 
behavior. While it is tempting to regard the anxiety-reducing 
effect of a TPH2 inhibitor in animals displaying both enhanced 
anxiety and enhanced TPH2 expression as support for differ-
ences in serotonergic transmission to be of importance for the 
differences in anxiety, the possibility that the lack of an anxi-
ety-reducing effect of p-CPA in HO rats reflects merely a ceil-
ing effect should not be excluded. The fact that the anxiolytic 
effect of benzodiazepines in the same paradigm has never been 
reported to be confined to a specific subset of the tested animals 
however argues against this possibility; for example, in a study 
comparing Wistar rats selectively bred to display high (HAB) or 
low (LAB) anxiety-like behavior on the basis of their EPM perfor-
mance, both strains displayed an anxiolytic-like response to a 
Figure 3. Time spent on (A) and entries made onto (B) open arms by animals receiving either saline or paroxetine. The upper graphs show otherwise untreated animals; 
the lower graphs show animals administered escitalopram p.o. for 5 weeks. Values are given as means ± SEM. (n = 10 in all groups). Significance symbols (*/n.s.) associ-
ated with a specific bar in the upper graph represent level of significance for the difference between rats of the same group (high open arm [HO] and low open arm [LO], 
respectively) given saline or paroxetine. Significance symbols (†/n.s.) associated with a specific bar in the lower graphs represent differences between the indicated 
group (having received escitalopram) and the corresponding group in the upper graphs (having received control pellets). n.s. nonsignificant, *†P < .05, ††P < .01, ***P < .001. 
Comparisons of the different groups displayed in the lower graph revealed no significant differences.
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benzodiazepine, the difference between HAB and LAB remain-
ing significant in treated animals (Liebsch et al., 1998).
It should also be underlined that the observed effects of 
p-CPA in LO and HO rats, respectively, refute the possibility that 
the apparent increase in serotonergic transmission in LO rats 
should be regarded as a compensatory mechanism aiming to 
dampen anxiety enhanced by other mechanisms; thus, had this 
been the case, p-CPA should enhance anxiety-like behavior in 
LO animals and amplify rather than counteract the difference 
between LO and HO animals. Likewise, had serotonin exerted 
an anxiety-dampening influence, administration of paroxetine 
should have enhanced rather than further reduced open arm 
activity in LO rats.
When interpreting the TPH2 elevation observed in the pre-
sent study, it should be noted that LO rats displayed enhanced 
expression not only of TPH2 but also of other genes encoding 
proteins expressed by serotonergic neurons, such as the mon-
oamine oxidase subtype expressed by serotonergic neurons 
(MAO-B), the serotonin transporter, aromatic L-amino acid 
decarboxylase, and a transcription factor of importance for the 
development of these neurons, fev. LO rats hence seem char-
acterized either by a more developed serotonergic network or 
by serotonergic neurons displaying a more active transcrip-
tion machinery compared with less anxious animals. The 
notion that LO rats are characterized by a stronger serotonergic 
innervation gains indirect support from a report by Keck and 
co-workers (2005) showing the above-mentioned HAB rats to 
display enhanced serotonin transporter binding in hippocam-
pus and enhanced serotonin release in the same brain region 
when exposed to a stressor (in the form of an EPM session) in 
conjunction with serotonin reuptake inhibition. In the present 
study, serotonin levels were unfortunately not assessed using 
microdialysis but merely in brain homogenates, and the ani-
mals had not been exposed to a stressor shortly before sacrifice. 
It should be noted, however, that LO rats did display higher lev-
els of serotonin in a brain region of critical importance for the 
regulation of anxiety, the amygdala; in contrast, no differences 
were observed in hippocampus or striatum. The lack of increase 
in the levels of the serotonin metabolite 5-HIAA in the amygdala 
of LO rats supports the notion that these animals, when in a 
restful situation, are not characterized by enhanced serotonin 
turnover.
Acute administration of an SRI to rodents causes elevated 
extracellular levels of serotonin in many (but not all) of the brain 
regions innervated by serotonergic nerve terminals (Rutter and 
Auerbach, 1993), which is well in line with the observation that 
this treatment, both in animals and humans, exerts a prompt 
dampening influence on functions that are normally under 
an inhibitory influence of serotonin, such as sexual behavior 
(McMahon, 2011) and anger/aggression (Landén et  al., 2009). 
Previous studies (Griebel et  al., 1994; Silva et  al., 1999; Borsini 
et al., 2002; Drapier et al., 2007) suggesting acute administration 
of SRIs to exert an anxiogenic-like effect in the EPM are hence 
highly compatible with the notion that serotonin exerts an anx-
iety-enhancing effect in this paradigm. In the same vein, we also 
observed acute administration of an SRI, paroxetine, to exert an 
anxiety-enhancing effect, but only in the LO group. It is not far-
fetched to suggest that this difference between HO and LO rats 
with respect to the response to an indirect serotonin agonist is 
the result of LO rats displaying a more developed network of 
serotonergic nerve terminals and/or a larger capacity for sero-
tonin formation; likewise, it may be speculated that the initial 
anxiogenic effect of SRIs in patients with anxiety disorders, 
such as panic disorder, which is seldom observed in nonanxious 
subjects, may be similarly explained. Notably, a study aiming to 
assess brain serotonin turnover by measuring jugular vein over-
flow of the serotonin metabolite 5-hydroxyindole acetic acid 
found support for a considerable increase in serotonin turnover 
in subcortical areas in patients with panic disorder (Esler et al., 
2007).
It may seem unexpected that LO rats displayed enhanced 
expression of the serotonin transporter, given that anxiety-
related traits in humans have been associated with the s 
allele of a polymorphism in the promoter of the serotonin 
transporter gene causing reduced expression of this protein 
(Sen et  al., 2004). However, as discussed above, we suggest 
the enhanced expression of the serotonin transporter in LO 
rats to reflect an increase in the number of serotonergic neu-
rons (or in the transcriptional activity of these) rather than an 
increase in the number of transporters per serotonergic neu-
ron. While the net effect of the s allele on serotonergic output, 
taking also the possible effect during brain development into 
consideration, remains elusive, it is in fact not unlikely that 
this allele causes enhanced serotonergic output (as the result 
of impaired reuptake inhibition), which would be well in line 
with the results of this paper.
Likewise, it may seem counter-intuitive that proneness for 
anxiety should be associated with, and to some extent caused 
by, enhanced serotonergic output, given that SRIs, which are 
usually assumed to facilitate serotonergic transmission, are 
effective for most major anxiety disorders (Den Boer and 
Westenberg, 1988; Modigh et al., 1992; Nutt et al., 1999; Zohar 
and Westenberg, 2000). However, as discussed above, the anx-
iety-reducing effect of SRIs, unlike, for example, the effects of 
the same drugs on sexual functioning (McMahon et  al. 2011), 
on certain forms of anger and irritability (for refs, see Eriksson, 
1999), and on affective lability (for refs, see Landén et al., 2009), 
requires long-term administration. Theoretically, this discrep-
ancy may be explained by differences in the regulation of those 
serotonergic neurons regulating anxiety on the one hand and 
those influencing sexual behavior and anger on the other, the 
former but not the latter requiring long-term SRI administra-
tion for an enhancement of serotonergic output to be at hand. 
However, given the anxiogenic effect of acute SRI administration 
observed both in humans and rodents, an alternative possibility, 
according to which the delayed onset of action might instead be 
explained in terms of an adaptive downregulation of the influ-
ence of anxiety-provoking serotonergic synapses (Salchner and 
Singewald, 2006; Graeff and Zangrossi, 2010, Lazary et al., 2011), 
appears at least as attractive.
Previous studies on the possible influence of long-term SRI 
administration on the EPM paradigm (in rats not characterized 
with respect to baseline anxiety) have failed to reveal consistent 
results, some but not all showing a modest anxiogenic-like effect 
(Borsini et al., 2002). In the present study, long-term administra-
tion of escitalopram by the per oral route neither enhanced nor 
reduced baseline EPM behavior in LO rats but blunted the anx-
iogenic-like response to acute administration of paroxetine in 
these animals, so that HO and LO rats did no longer differ with 
respect to how they responded to this provocation.
It hence seems as if subchronic administration of an SRI 
in animals displaying enhanced baseline anxiety-like behav-
ior, as well as indices of enhanced serotonergic neurotrans-
mission, does lead to a downregulation of the anxiogenic-like 
influence of serotonin as reflected by the enhanced anxiety-
like behavior elicited by acute SRI administration. In line with 
this, Salchner and Singewald (2006) reported chronic treatment 
with fluoxetine to counteract the potentiating effect of acute 
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fluoxetine administration on both escape behavior and fos 
expression induced by airjet provocation in Sprague-Dawley 
rats. Downregulation of postsynaptic 5HT2C receptors, or struc-
tures beyond these, is one possible underlying mechanism for 
such an adaptive response to long-term SRI administration 
(Bristow et al., 2000).
When evaluating the inability of subchronic escitalopram to 
reduce baseline anxiety in LO animals, it should be considered 
that all animals, when retested under the influence of escitalo-
pram, had been exposed to the EPM at an earlier occasion (ie, 
when being categorized as LO and HO, respectively). Previous 
studies thus suggest that prior experience of the test may abol-
ish the anxiolytic effect of drugs such as benzodizapines (File 
et al., 1990). Although we did take precautions to minimize the 
influence of this one-trial tolerance phenomenon by undertak-
ing the 2 EPM tests in different rooms (Schneider et  al., 2011) 
and in spite of the fact that several weeks elapsed between the 2 
tests (which is also reported to counteract this effect), it cannot 
be excluded that this factor nevertheless precluded the chance 
of detecting an anxiolytic effect of subchronic escitalopram 
administration. However, it should be noted that p-CPA did exert 
an anxiolytic effect in LO animals in spite of the fact that they 
had previous experience of the paradigm.
While long-term escitalopram treatment thus reduced the 
anxiety elicited by acute paroxetine in LO rats but failed to alter 
baseline anxiety-like behavior in these animals, HO animals 
exposed to the same treatment displayed enhanced baseline 
anxiety-like behavior, hence eliminating also this difference 
between HO and LO rats. Tentatively, the dominating net effect 
of long-term administration of SRIs on the serotonergic syn-
apses regulating the studied behavior in these animals is to 
exert a modest enhancement from a low starting point rather 
than to downregulate an excessive influence.
The aim of experiment I was not only to assess the possible 
association between EPM performance and brain serotonergic 
activity but also to explore to what extent HO and LO rats differ 
with respect to another behavior tentatively reflecting human 
anxiety, unconditioned acoustic startle. While a study on the 
above-mentioned HAB and LAB rats, bred on the basis of EPM per-
formance, suggests rats with high anxiety, as assessed using EPM, 
to display lower unconditioned (as well as fear-sensitized) startle 
than LAB animals (Yilmazer-Hanke et al., 2004), we observed no 
difference in this regard between LO and HO rats, which is well in 
line with previous studies showing no correlation between EPM 
and startle (Yilmazer-Hanke et al., 2002; de Oliveira et al., 2011). 
Prompted by the considerable comorbidity between anxiety disor-
ders and depression, we also exposed our animals to a paradigm 
claimed to reflect depressive-like behavior, that is, the forced-
swim test. Again, however, no difference between LO and HO rats 
was found, a finding in line with an earlier study also assessing 
rats subdivided on the basis of EPM performance (Ho et al., 2002).
This study has certain limitations. First, while the EPM para-
digm having bearing on human anxiety gains support from the 
fact that GABA A-receptor-activating anxiolytics reliably reduce 
anxiety-like behavior in this model (Pellow and File, 1986) while 
drugs known to be anxiogenic in man exert the opposite effect 
(Yeung et al., 2013), it should be acknowledged that the possible 
relationship between the EPM paradigm and the various forms 
of human anxiety, including panic anxiety (Graeff and Zangrossi, 
2010), is far from clear-cut. Thus, other factors, such as impulsiv-
ity (Soubrié, 1986), could also be of importance for the studied 
behavior. It is, for example, not inconceivable that the reduc-
tion in time spent on open arms in LO rats upon subchronic 
administration of escitalopram may reflect reduced impulsivity 
rather than enhanced anxiety-like behavior (Thiébot et al., 1985; 
Cherek et al., 2002). Second, we did not address the possibility 
that different serotonergic pathways originating in different 
raphe nuclei may exert differential effects on the studied behav-
ior (Donner et al., 2012; Paul and Lowry, 2013). Third, it cannot 
be excluded that the 2 behavioral stressors to which all animals 
in experiment I were exposed between the first EPM and sacri-
fice, that is, the acoustic startle test and the forced swim stress, 
may exert a lasting impact on brain serotonergic transmission, 
hence contributing to the observed association between EPM 
behavior and serotonergic activity. Fourth, we have, in this study, 
refrained from exploring the possible differences between HO 
and LO rats with respect to other neurotransmitters that have 
been attributed importance for inter-individual differences in 
anxiety and that may interact with serotonin in this regard, such 
as the endocannabinoids (Lazary et al., 2009).
The major novel conclusions of the present data are that: 
1) inter-individual differences within a batch of Wistar rats can 
be utilized to study the influence of serotonin on anxiety-like 
behavior, 2)  enhanced serotonergic activity is not only associ-
ated with enhanced anxiety-like behavior but also seems to be 
an important causal factor underlying inter-individual differ-
ences in this regard, 3) the anxiogenic effect of acute adminis-
tration of an SRI in Wistar rats is more pronounced in animals 
with enhanced baseline anxiety-like behavior than in those 
with low anxiety (hence corresponding to the human situ-
ation), and 4)  subchronic administration of an SRI blunts the 
anxiogenic effect of the acute administration of another SRI in 
animals with high anxiety-like behaviour at baseline. Our data 
support the view that proneness for anxiety in humans may 
also be partly caused by an enhanced anxiogenic influence of 
serotonin and that this is the reason why acute administration 
of an SRI may elicit anxiety in susceptible individuals while 
subchronic administration of the same agents often have the 
opposite effect.
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